Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 149709-44-4 Chemical Structure| 149709-44-4

Structure of Sacubitrilat
CAS No.: 149709-44-4

Chemical Structure| 149709-44-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sacubitrilat, namely LBQ-657, is an inhibitor of endopeptidase and effective for hypertension and heart failure. Sacubitrilat is one of the impurities of sacubitril.

Synonyms: LBQ-657; Desethyl Sacubitril; Sac

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sacubitrilat

CAS No. :149709-44-4
Formula : C22H25NO5
M.W : 383.44
SMILES Code : O=C(O)[C@H](C)C[C@H](NC(CCC(O)=O)=O)CC1=CC=C(C2=CC=CC=C2)C=C1
Synonyms :
LBQ-657; Desethyl Sacubitril; Sac
MDL No. :MFCD00921225
InChI Key :DOBNVUFHFMVMDB-BEFAXECRSA-N
Pubchem ID :10430040

Safety of Sacubitrilat

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H336-H372
Precautionary Statements:P260-P264-P270-P271-P304+P340+P312-P314-P403+P233-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Flp-In 293 cell lines 200 µM 10 minutes To evaluate the impact of CES1 variant G143E on sacubitril activation, and found that G143E is a loss-of-function variant for sacubitril activation. Drug Metab Dispos. 2016 Apr;44(4):554-9
Recombinant human CES2 200 µM 10 minutes To confirm that sacubitril is not a substrate of CES2. Drug Metab Dispos. 2016 Apr;44(4):554-9
Recombinant human CES1 200 µM 10 minutes To confirm that sacubitril is a selective CES1 substrate. Drug Metab Dispos. 2016 Apr;44(4):554-9
Murine ventricular cardiomyocytes 40 µM 15 minutes To investigate the effects of Sacubitrilat on pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in murine ventricular cardiomyocytes, results showed that Sacubitrilat significantly reduced Ca2+ leak. ESC Heart Fail. 2020 Oct;7(5):2992-3002
Fetal human cardiac fibroblasts 20 µM 16 hours To evaluate the effect of sacubitrilat in combination with ANP or ADM on collagen expression. Results showed that sacubitrilat combined with ANP reduced Col1a2 expression, while sacubitrilat combined with ADM did not show similar effects. ESC Heart Fail. 2025 Apr;12(2):1304-1315
Mouse primary renal tubular epithelial cells (RTECs) 10 µM 24 hours To evaluate the effect of Sacubitrilat on TGF-β1-induced fibrosis and ferroptosis, results showed that Sacubitrilat significantly inhibited the expression of fibrosis and ferroptosis-related proteins. MedComm (2020). 2023 Jul 14;4(4):e330
Mouse kidney tubular epithelium cells (TCMK-1) 10 µM 24 hours To evaluate the effect of Sacubitrilat on TGF-β1-induced fibrotic phenotypes, results showed that Sacubitrilat significantly inhibited the expression of fibrotic proteins. MedComm (2020). 2023 Jul 14;4(4):e330
Human ventricular cardiomyocytes 40 µM 30 minutes To investigate the effects of Sacubitrilat on pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes from patients with end-stage heart failure, results showed that Sacubitrilat significantly reduced Ca2+ leak. ESC Heart Fail. 2020 Oct;7(5):2992-3002
MDA-MB-231 (triple-negative breast cancer cells) 23.02 μg/mL 48 hours To evaluate the inhibitory effect of Sacubitrilat on the proliferation of triple-negative breast cancer cells, showing an IC50 of 23.02 μg/mL. Sci Rep. 2023 Jun 19;13(1):9952
SW-480 (colorectal cancer cells) 14.07 μg/mL 48 hours To evaluate the inhibitory effect of Sacubitrilat on the proliferation of colorectal cancer cells, showing an IC50 of 14.07 μg/mL. Sci Rep. 2023 Jun 19;13(1):9952

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Unilateral ureteral obstruction (UUO) and adenine diet-induced chronic kidney disease models Oral gavage 30 mg/kg/day Once daily for 7 days (UUO model) or 14 days (adenine model) To evaluate the effect of Sacubitrilat on kidney fibrosis, results showed that Sacubitrilat significantly alleviated kidney fibrosis, tubular injury, and inflammatory responses. MedComm (2020). 2023 Jul 14;4(4):e330
Sprague-Dawley rats Myocardial infarction model Oral gavage 68 mg/kg/day Once daily for 42 days To evaluate the effects of Sac/Val on regional function and remodeling post-MI. Results showed that Sac/Val reduced left ventricular end-diastolic volume, preserved systolic strain in the proximal zone, and reduced fibrotic deposition and pro-apoptotic signaling. ESC Heart Fail. 2025 Apr;12(2):1304-1315

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.61mL

0.52mL

0.26mL

13.04mL

2.61mL

1.30mL

26.08mL

5.22mL

2.61mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories